Your browser doesn't support javascript.
loading
Altered perivascular fibroblast activity precedes ALS disease onset.
Månberg, Anna; Skene, Nathan; Sanders, Folkert; Trusohamn, Marta; Remnestål, Julia; Szczepinska, Anna; Aksoylu, Inci Sevval; Lönnerberg, Peter; Ebarasi, Lwaki; Wouters, Stefan; Lehmann, Manuela; Olofsson, Jennie; von Gohren Antequera, Inti; Domaniku, Aylin; De Schaepdryver, Maxim; De Vocht, Joke; Poesen, Koen; Uhlén, Mathias; Anink, Jasper; Mijnsbergen, Caroline; Vergunst-Bosch, Hermieneke; Hübers, Annemarie; Kläppe, Ulf; Rodriguez-Vieitez, Elena; Gilthorpe, Jonathan D; Hedlund, Eva; Harris, Robert A; Aronica, Eleonora; Van Damme, Philip; Ludolph, Albert; Veldink, Jan; Ingre, Caroline; Nilsson, Peter; Lewandowski, Sebastian A.
Afiliação
  • Månberg A; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.
  • Skene N; Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
  • Sanders F; Division of Neuroscience, Department of Brain Sciences, Imperial College London, London, UK.
  • Trusohamn M; United Kingdom Dementia Research Institute, London, UK.
  • Remnestål J; Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
  • Szczepinska A; Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
  • Aksoylu IS; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.
  • Lönnerberg P; Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
  • Ebarasi L; Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
  • Wouters S; Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
  • Lehmann M; Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
  • Olofsson J; Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
  • von Gohren Antequera I; Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.
  • Domaniku A; Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.
  • De Schaepdryver M; Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
  • De Vocht J; Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
  • Poesen K; Laboratory for Neurobiomarker Research, Department of Neurology, Leuven Brain Institute, KU Leuven (University of Leuven), Leuven, Belgium.
  • Uhlén M; Neurology Department and Center for Brain & Disease Research, KU Leuven, VIB, Leuven, Belgium.
  • Anink J; Laboratory for Neurobiomarker Research, Department of Neurology, Leuven Brain Institute, KU Leuven (University of Leuven), Leuven, Belgium.
  • Mijnsbergen C; Laboratory Medicine, UZ Leuven (University Hospital Leuven), Leuven, Belgium.
  • Vergunst-Bosch H; Division of Systems Biology, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.
  • Hübers A; Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.
  • Kläppe U; Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
  • Rodriguez-Vieitez E; Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
  • Gilthorpe JD; UMC Utrecht Brain Center, University Medical Center Utrecht, Department of Neurology, Utrecht University, Utrecht, the Netherlands.
  • Hedlund E; University of Ulm, Neurology Clinic, Ulm, Germany.
  • Harris RA; Division of Neurology, Geneva University Hospital, Geneva, Switzerland.
  • Aronica E; Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
  • Van Damme P; Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
  • Ludolph A; Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.
  • Veldink J; Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.
  • Ingre C; Department of Clinical Neuroscience, Karolinska Institute, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
  • Nilsson P; Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
  • Lewandowski SA; Neurology Department and Center for Brain & Disease Research, KU Leuven, VIB, Leuven, Belgium.
Nat Med ; 27(4): 640-646, 2021 04.
Article em En | MEDLINE | ID: mdl-33859435
Apart from well-defined factors in neuronal cells1, only a few reports consider that the variability of sporadic amyotrophic lateral sclerosis (ALS) progression can depend on less-defined contributions from glia2,3 and blood vessels4. In this study we use an expression-weighted cell-type enrichment method to infer cell activity in spinal cord samples from patients with sporadic ALS and mouse models of this disease. Here we report that patients with sporadic ALS present cell activity patterns consistent with two mouse models in which enrichments of vascular cell genes preceded microglial response. Notably, during the presymptomatic stage, perivascular fibroblast cells showed the strongest gene enrichments, and their marker proteins SPP1 and COL6A1 accumulated in enlarged perivascular spaces in patients with sporadic ALS. Moreover, in plasma of 574 patients with ALS from four independent cohorts, increased levels of SPP1 at disease diagnosis repeatedly predicted shorter survival with stronger effect than the established risk factors of bulbar onset or neurofilament levels in cerebrospinal fluid. We propose that the activity of the recently discovered perivascular fibroblast can predict survival of patients with ALS and provide a new conceptual framework to re-evaluate definitions of ALS etiology.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vasos Sanguíneos / Fibroblastos / Esclerose Lateral Amiotrófica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vasos Sanguíneos / Fibroblastos / Esclerose Lateral Amiotrófica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suécia